TCGA-AN-A0FL-01A-11R-A034-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 8
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- CHOLESTEROL_HOMEOSTASIS+0.450
- FATTY_ACID_METABOLISM+0.390
- ADIPOGENESIS+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- NOTCH_SIGNALING+0.330
- GLYCOLYSIS+0.290
- PEROXISOME+0.280
- BILE_ACID_METABOLISM+0.270
- UV_RESPONSE_UP+0.260
Top 10 suppressed
- MITOTIC_SPINDLE-0.360
- ALLOGRAFT_REJECTION-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- IL6_JAK_STAT3_SIGNALING-0.250
- UV_RESPONSE_DN-0.230
- ESTROGEN_RESPONSE_EARLY-0.210
- TNFA_SIGNALING_VIA_NFKB-0.210
- TGF_BETA_SIGNALING-0.190
- E2F_TARGETS-0.180
- G2M_CHECKPOINT-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 148130 | EPN | Supratentorial EPN | 0.797 |
| 2 | 130692 | EPN | Supratentorial EPN | 0.753 |
| 3 | BS_AVYNZHSB | subependymal giant cell astrocytoma(SEGA) | — | 0.729 |
| 4 | 486430aa-f745-4353-9e03-6226ac8d9993 | — | — | 0.722 |
| 5 | SRR4296070 | — | cohortA1 | 0.715 |
| 6 | SRR9879284 | — | cohortA1 | 0.694 |
| 7 | SRR6013510 | — | cohortA4 | 0.690 |
| 8 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.687 |
| 9 | AUR-AD9F-TTM3-A-1-1-R-A542-39 | — | C | 0.682 |
| 10 | e84aa97b-e429-4994-acef-2b57be71fe9a | — | — | 0.682 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.450 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |